• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性硬化性胆管炎近期治疗方案概述

An overview of recent treatment options for primary sclerosing cholangitis.

作者信息

Mousavere Ioanna, Kalampokis Georgios, Fousekis Fotios, Karayiannis Peter, Baltayiannis Gerasimos, Christodoulou Dimitrios

机构信息

Department of Gastroenterology, University Hospital of Ioannina, Greece (Ioanna Mousavere, Fotios Fousekis, Gerasimos Baltayiannis, Dimitrios Christodoulou).

Department of Internal Medicine, University Hospital of Ioannina, Greece (Georgios Kalampokis, Gerasimos Baltayiannis, Dimitrios Christodoulou).

出版信息

Ann Gastroenterol. 2023 Nov-Dec;36(6):589-598. doi: 10.20524/aog.2023.0834. Epub 2023 Oct 30.

DOI:10.20524/aog.2023.0834
PMID:38023975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10662072/
Abstract

Primary sclerosing cholangitis (PSC) is a chronic hepatic dysfunction characterized by inflammatory and tissue-degenerative strictures of the biliary tree, leading to cirrhosis and cholangiocarcinoma. The pathophysiological mechanisms involve immune-mediated responses. Numerous treatment modalities targeting the inflammatory aspects have been suggested, but a consensus on the best treatment option is lacking. This study aims to review the most up-to-date treatment options for PSC.

摘要

原发性硬化性胆管炎(PSC)是一种慢性肝功能障碍,其特征为胆管树的炎症性和组织退行性狭窄,可导致肝硬化和胆管癌。病理生理机制涉及免疫介导的反应。已经提出了许多针对炎症方面的治疗方法,但对于最佳治疗方案尚未达成共识。本研究旨在综述PSC的最新治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b479/10662072/efd3f4ff3226/AnnGastroenterol-36-589-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b479/10662072/efd3f4ff3226/AnnGastroenterol-36-589-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b479/10662072/efd3f4ff3226/AnnGastroenterol-36-589-g003.jpg

相似文献

1
An overview of recent treatment options for primary sclerosing cholangitis.原发性硬化性胆管炎近期治疗方案概述
Ann Gastroenterol. 2023 Nov-Dec;36(6):589-598. doi: 10.20524/aog.2023.0834. Epub 2023 Oct 30.
2
An update on treatment options for primary sclerosing cholangitis.原发性硬化性胆管炎治疗方案的最新进展。
Gastroenterol Hepatol Bed Bench. 2020 Spring;13(2):115-124.
3
Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.原发性硬化性胆管炎的 MRI 和 MR 胆胰管成像报告标准:国际原发性硬化性胆管炎研究组磁共振工作组指南。
Eur Radiol. 2022 Feb;32(2):923-937. doi: 10.1007/s00330-021-08147-7. Epub 2021 Aug 6.
4
Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.干扰素-γ 依赖性免疫应答有助于小鼠硬化性胆管炎的发病机制。
J Hepatol. 2019 Oct;71(4):773-782. doi: 10.1016/j.jhep.2019.05.023. Epub 2019 Jun 5.
5
[Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].[原发性硬化性胆管炎和原发性胆汁性胆管炎的新见解]
Korean J Gastroenterol. 2020 May 25;75(5):246-256. doi: 10.4166/kjg.2020.75.5.246.
6
Sclerosing cholangitis.硬化性胆管炎
Curr Opin Gastroenterol. 2006 May;22(3):288-93. doi: 10.1097/01.mog.0000218966.78558.67.
7
An update on primary sclerosing cholangitis.原发性硬化性胆管炎的最新进展。
Curr Opin Gastroenterol. 2008 May;24(3):377-83. doi: 10.1097/MOG.0b013e3282f9e239.
8
Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.金属支架、磁铁还是肝移植:原发性硬化性胆管炎伴狭窄的治疗选择。
Hepatol Int. 2018 Nov;12(6):510-519. doi: 10.1007/s12072-018-9906-6. Epub 2018 Nov 14.
9
MR Imaging in Primary Sclerosing Cholangitis and Other Cholangitis.磁共振成像在原发性硬化性胆管炎和其他胆管炎中的应用。
Radiol Clin North Am. 2022 Sep;60(5):843-856. doi: 10.1016/j.rcl.2022.05.007. Epub 2022 Jul 8.
10
Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.自身免疫性胆道疾病:原发性胆汁性胆管炎和原发性硬化性胆管炎。
Pathologica. 2021 Jun;113(3):170-184. doi: 10.32074/1591-951X-245.

引用本文的文献

1
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial.HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性:一项随机双盲2a期试验。
Clin Mol Hepatol. 2025 Jan;31(1):119-130. doi: 10.3350/cmh.2024.0629. Epub 2024 Sep 24.
2
Berberine ameliorates the progression of primary sclerosing cholangitis by activating farnesoid X receptor.小檗碱通过激活法尼醇 X 受体改善原发性硬化性胆管炎的进展。
Cell Biochem Biophys. 2024 Jun;82(2):767-776. doi: 10.1007/s12013-024-01226-8. Epub 2024 Feb 8.

本文引用的文献

1
Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.拉苏昔醇(DUR-928)治疗酒精性肝炎的安全性、药代动力学和疗效信号。
Am J Gastroenterol. 2024 Jan 1;119(1):107-115. doi: 10.14309/ajg.0000000000002275. Epub 2023 Apr 3.
2
Oral hymecromone decreases hyaluronan in human study participants.口服海曲泊帕乙醇胺可降低人类研究参与者的透明质酸。
J Clin Invest. 2022 May 2;132(9). doi: 10.1172/JCI157983.
3
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
原发性硬化性胆管炎患者中 Cenicriviroc 的疗效和安全性:PERSEUS 研究。
Hepatol Commun. 2020 Dec 22;5(3):478-490. doi: 10.1002/hep4.1619. eCollection 2021 Mar.
4
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.一项奥贝胆酸治疗原发性硬化性胆管炎的随机、安慰剂对照、II 期研究。
J Hepatol. 2020 Jul;73(1):94-101. doi: 10.1016/j.jhep.2020.02.033. Epub 2020 Mar 10.
5
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis.肿瘤坏死因子拮抗剂对原发性硬化性胆管炎患者的影响。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2295-2304.e2. doi: 10.1016/j.cgh.2020.02.014. Epub 2020 Feb 15.
6
Bile acid metabolites control T17 and T cell differentiation.胆汁酸代谢物控制 T17 和 T 细胞分化。
Nature. 2019 Dec;576(7785):143-148. doi: 10.1038/s41586-019-1785-z. Epub 2019 Nov 27.
7
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.多种治疗靶点在罕见胆汁淤积性肝病中的应用:是时候重新定义治疗策略了。
Ann Hepatol. 2020 Jan-Feb;19(1):5-16. doi: 10.1016/j.aohep.2019.09.009. Epub 2019 Oct 31.
8
Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.抗生素治疗原发性硬化性胆管炎伴或不伴炎症性肠病的效果:系统评价和荟萃分析。
Semin Liver Dis. 2019 Nov;39(4):432-441. doi: 10.1055/s-0039-1688501. Epub 2019 Jul 17.
9
Alterations of the bile microbiome in primary sclerosing cholangitis.原发性硬化性胆管炎胆汁微生物组的改变。
Gut. 2020 Apr;69(4):665-672. doi: 10.1136/gutjnl-2019-318416. Epub 2019 Jun 26.
10
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.英国胃肠病学会和英国PSC 指南:原发性硬化性胆管炎的诊断和管理。
Gut. 2019 Aug;68(8):1356-1378. doi: 10.1136/gutjnl-2018-317993. Epub 2019 Jun 1.